VCIM
FDMT icon

Velan Capital Investment Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Velan Capital Investment Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,000
Closed -$44.5K – 52
2025
Q2 		$44.5K Hold
12,000
– – 0.04% 47
2025
Q1 		$38.8K Buy
12,000
+2,000
+20% +$9.42K 0.04% 42
2024
Q4 		$55.7K Buy
+10,000
New +$78.5K 0.05% 35

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Velan Capital Investment Management's FDMT Position: Q3 2025 in Review

Velan Capital Investment Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2025, closing a stake of 12,000 shares — an estimated $44.5K sold.

Velan Capital Investment Management first reported a position in FDMT in Q4 2024 and held it in 3 quarters. The position peaked at $55.7K in Q4 2024. 134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

  • Velan Capital Investment Management reported no remaining 4D Molecular Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Velan Capital Investment Management sold 12,000 4D Molecular Therapeutics shares in Q3 2025, an estimated $44.5K.
  • Velan Capital Investment Management first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 3 quarters.
  • Velan Capital Investment Management's 4D Molecular Therapeutics position peaked at $55.7K in Q4 2024.
  • 134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on Velan Capital Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.